Assessing Neurodegenerative Diseases: High-Sensitivity Technologies That Assay Pathological Biomarkers in Blood

Assessing Neurodegenerative Diseases: High-Sensitivity Technologies That Assay Pathological Biomarkers in Blood

Assessing Neurodegenerative Diseases: High-Sensitivity Technologies That Assay Pathological Biomarkers in Blood

Overview & Key Highlights

• Covers detection assays for neurodegenerative diseases

• Focuses exclusively on blood-based biomarkers for neurodegenerative diseases

• Includes clinical perspective for each assay

Access Information

Available via Springer. Log in through an institution or access the eBook version directly.

Publication Details

Published in 2026 by Springer Nature Switzerland. Comprehensive focus on high-sensitivity blood assays.

© MagQu

Previous
Previous

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

Next
Next

Changes in Plasma Amyloid β 1–42 Peptide and Total Tau Protein from Normal Cognition to Severe-Stage Alzheimer’s Disease Using an Immunomagnetic Reduction Assay